全球局部用藥研發生產機構（CDMO）市場規模、佔有率、趨勢及成長分析報告（2026-2034）

全球外用藥物CDMO市場預計將從2025年的591億美元成長至2034年的1,514.1億美元，2026年至2034年的複合年成長率（CAGR）為11.02%。由於藥物研發和生產業務外包的日益普及，全球外用藥物CDMO市場正經歷穩定成長。合約研發生產機構（CDMO）為乳膏、凝膠、軟膏和經皮貼劑等製劑提供配方、生產和包裝服務。對皮膚病和疼痛管理治療的需求不斷成長，正在推動市場擴張。製藥公司越來越依賴CDMO來降低成本並縮短產品上市時間。

關鍵成長要素包括皮膚疾病盛行率的上升和對個人化醫療日益成長的需求。合約研發生產機構 (CDMO) 提供專業技術、合規性和高度擴充性的生產能力。藥物遞送技術的進步正在提高產品的療效和穩定性。此外，對非專利外用藥物的需求不斷成長也推動了外包活動。

市場預計將受益於藥品研發管線的擴張和研發投入的增加。醫療保健產業的新興市場將創造新的外包機會。各公司正致力於先進的製劑技術和永續的生產實務。隨著製藥公司將效率和創新放在首位，全球外用藥物開發、生產和製造組織（CDMO）市場預計將長期保持穩定成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球外用藥物CDMO市場：依產品類型分類

• 市場分析、洞察與預測
• 半固態製劑（乳膏、軟膏、凝膠和其他半固態製劑）
• 液體
• 經皮製劑
• 固態劑型

第5章 全球局部用藥研發與生產機構（CDMO）市場：依治療領域分類

• 市場分析、洞察與預測
• 皮膚科
• 疼痛管理
• 創傷護理
• 眼科
• 其他治療領域

第6章 全球外用藥物CDMO市場：依服務類型分類

• 市場分析、洞察與預測
• 契約製造
• 合約開發

第7章 全球外用藥物CDMO市場：依最終用途分類

• 市場分析、洞察與預測
• 製藥公司
• 生技公司
• 其他最終用戶

第8章 全球外用藥物CDMO市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Ascendia Pharmaceuticals
  • Bora Pharmaceuticals Co.Ltd
  • Cambrex Corporation
  • Contract Pharmaceuticals Limited
  • CoreRx Inc
  • Famar SA
  • Groupe PARIMA Inc
  • Lonza Group AG
  • LTS Lohmann Therapie-Systeme AG（Tapemark Company）
  • Lubrizol Life Science Health（The Lubrizol Corporation）
  • MedPharm Ltd.（Tergus Pharma LLC）
  • NextPharma Technologies Holding Limited
  • Noramco（Halo Pharmaceutical Inc.）
  • Novo Holdings A/S（Catalent Inc.）
  • PCI Pharma Services
  • Pierre Fabre Group
  • Piramal Pharma Solutions
  • Recipharm AB
  • Symbio Proinnovera（Dow Development Laboratories LLC）
  • UPM Pharmaceuticals Inc
  • Viatris Inc.（DPT Laboratories）

The global topical drugs CDMO market size is expected to reach USD 151.41 Billion in 2034 from USD 59.10 Billion in 2025, growing at a CAGR of 11.02 during 2026-2034.The Global Topical Drugs CDMO Market is growing steadily due to increasing outsourcing of drug development and manufacturing activities. Contract Development and Manufacturing Organizations (CDMOs) provide formulation, production, and packaging services for creams, gels, ointments, and transdermal patches. Rising demand for dermatological and pain management treatments is supporting market expansion. Pharmaceutical companies are increasingly relying on CDMOs to reduce costs and accelerate time-to-market.

Key growth drivers include the increasing prevalence of skin disorders and growing demand for personalized medicine. CDMOs offer specialized expertise, regulatory compliance, and scalable manufacturing capabilities. Advancements in topical drug delivery technologies are improving product effectiveness and stability. Additionally, rising demand for generic topical medications is strengthening outsourcing activities.

Looking ahead, the market is expected to benefit from expanding pharmaceutical pipelines and increased R&D investments. Emerging markets with developing healthcare industries will create new outsourcing opportunities. Companies are focusing on advanced formulation technologies and sustainable manufacturing practices. As pharmaceutical firms prioritize efficiency and innovation, the Global Topical Drugs CDMO Market is projected to experience consistent long-term growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product Type

• Semi-Solid Formulations (Creams, Ointments, Gels, Other Semi-Solid Formulations)
• Liquid Formulations
• Transdermal Products
• Solid Formulations

By Therapeutic Area

• Dermatology
• Pain management
• Wound care
• Ophthalmology
• Other therapeutic areas

By Service Type

• Contract manufacturing
• Contract development

By End Use

• Pharmaceutical Companies
• Biotechnology Companies
• Other End Users

COMPANIES PROFILED

• Ascendia Pharmaceuticals, Bora Pharmaceuticals Co., Ltd., Cambrex Corporation, Contract Pharmaceuticals Limited, CoreRx Inc., Famar S.A., Groupe PARIMA Inc., Lonza Group AG, LTS Lohmann Therapie-Systeme AG (Tapemark Company), Lubrizol Life Science Health (The Lubrizol Corporation), MedPharm Ltd. (Tergus Pharma LLC), NextPharma Technologies Holding Limited, Noramco (Halo Pharmaceutical Inc.), Novo Holdings A/S (Catalent Inc.), PCI Pharma Services, Pierre Fabre Group, Piramal Pharma Solutions, Recipharm AB, Symbio Proinnovera (Dow Development Laboratories LLC), UPM Pharmaceuticals Inc., Viatris Inc. (DPT Laboratories)

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TOPICAL DRUGS CDMO MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Semi-Solid Formulations (Creams, Ointments, Gels, Other Semi-Solid Formulations) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Liquid Formulations Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Transdermal Products Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Solid Formulations Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL TOPICAL DRUGS CDMO MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapeutic Area
• 5.2. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Pain management Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Wound care Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Ophthalmology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Other therapeutic areas Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL TOPICAL DRUGS CDMO MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Service Type
• 6.2. Contract manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Contract development Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL TOPICAL DRUGS CDMO MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Other End Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL TOPICAL DRUGS CDMO MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product Type
  • 8.2.2 By Therapeutic Area
  • 8.2.3 By Service Type
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product Type
  • 8.3.2 By Therapeutic Area
  • 8.3.3 By Service Type
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product Type
  • 8.4.2 By Therapeutic Area
  • 8.4.3 By Service Type
  • 8.4.4 By End Use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product Type
  • 8.5.2 By Therapeutic Area
  • 8.5.3 By Service Type
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product Type
  • 8.6.2 By Therapeutic Area
  • 8.6.3 By Service Type
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL TOPICAL DRUGS CDMO INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Ascendia Pharmaceuticals
  • 10.2.2 Bora Pharmaceuticals Co.Ltd
  • 10.2.3 Cambrex Corporation
  • 10.2.4 Contract Pharmaceuticals Limited
  • 10.2.5 CoreRx Inc
  • 10.2.6 Famar S.A
  • 10.2.7 Groupe PARIMA Inc
  • 10.2.8 Lonza Group AG
  • 10.2.9 LTS Lohmann Therapie-Systeme AG (Tapemark Company)
  • 10.2.10 Lubrizol Life Science Health (The Lubrizol Corporation)
  • 10.2.11 MedPharm Ltd. (Tergus Pharma LLC)
  • 10.2.12 NextPharma Technologies Holding Limited
  • 10.2.13 Noramco (Halo Pharmaceutical Inc.)
  • 10.2.14 Novo Holdings A/S (Catalent Inc.)
  • 10.2.15 PCI Pharma Services
  • 10.2.16 Pierre Fabre Group
  • 10.2.17 Piramal Pharma Solutions
  • 10.2.18 Recipharm AB
  • 10.2.19 Symbio Proinnovera (Dow Development Laboratories LLC)
  • 10.2.20 UPM Pharmaceuticals Inc
  • 10.2.21 Viatris Inc. (DPT Laboratories)